clinical trial · NCT04242498
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
UCB Biopharma SRL·phase3·completed·n = 509
Hidradenitis SuppurativaBimekizumabPlacebo
brief summary
The purpose of the study is to evaluate the efficacy and safety of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)
started
Mar 2, 2020
primary completion
Nov 9, 2021
completion
Sep 28, 2022
last updated
May 19, 2026
official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol